AI Medication Adherence: 5 Ways AI Closes the Gap

Join us for the latest in our series, AI in healthcare. Learn how AI is transforming the way we track, predict, and promote medication adherence.

What is AI medication adherence?

AI medication adherence is the use of predictive models, smart devices, conversational AI, and drug-device combinations to help patients take their medications as prescribed. Machine learning identifies patients at risk of missing doses 7 to 30 days in advance. Connected pill bottles, mobile apps, and chatbots provide reminders, track usage, and surface adherence patterns pharmacists can act on.

Medication adherence, or the extent to which patients take their medications as prescribed, is a critical factor in managing chronic conditions. For treatment to be effective, patients need to take their medications at least 80% of the time. Overall, patient adherence rates are estimated to be around 50%. That means 50% of patients are non-adherent.

The consequences of non-adherence are significant. It can lead to poor health outcomes, shorter lifespans, increased hospitalizations, and more than $500 billion in avoidable healthcare costs each year linked to nonoptimized medication therapy. In the United States alone, approximately 125,000 deaths a year are linked to medication non-adherence.

How can we improve these outcomes? Artificial intelligence (AI) is emerging as a powerful tool to help patients stay on track. Here are five ways AI is making a difference:

  1. What predictive models can actually do

Machine-learning models that combine pharmacy claims, electronic health records (EHR)  data, connected-device signals, and social determinants of health can predict 7- to 30-day medication non-adherence with area under the curve values of 0.75 to 0.85. Pharmacists use the risk scores to prioritize outreach to patients who may be most likely to drop off therapy before they actually do.

These models have been validated in chronic conditions like type 2 diabetes and opioid use disorder, with similar accuracy across hypertension, heart failure, and oncology. The risk scores let pharmacy teams move from retrospective reporting to proactive intervention — identifying patients days or weeks before a missed refill would have flagged them.

Source: Solomon B. AI-Enabled Medication Adherence and Scalable Pharmacy Transformation. US Pharmacist. March 2026.

 

  1. How smart pill bottles track adherence

Electronic pill bottles record dosing events in real time, prompt patients about missed doses, and surface the data to the pharmacy team. Health-system specialty pharmacies and contract pharmacy programs deploy these for patients on high-cost or high-risk regimens when a missed dose has clinical consequences and the cost of intervention runs well below the cost of a hospital admission.

The evidence base for the approach is strong. In a randomized, virtual clinical trial of patients with multiple sclerosis, those who received pill-bottle reminders showed better adherence and were more likely to take their medication on time than those who did not (Rice et al). A study of breast cancer survivors found a 97.3% adherence rate among those who received reminders compared with 88.3% among those who did not (Park et al).

Smart pill bottles work best when pharmacists set the escalation logic and follow up on the patterns the device flags. The bottle generates the signal. The pharmacist closes the loop.

 

  1. Medication reminder apps and behavior tracking

Mobile apps designed for medication adherence prompt patients to take doses, log usage, and surface adherence trends the pharmacy team can review between visits. Health systems and specialty pharmacies use these apps inside post-discharge protocols and complex-therapy onboarding programs where patient persistence in the first 30, 60, and 90 days is the outcome that matters most.

A systematic review of mobile-app interventions found that consistent engagement with reminder apps correlates with better adherence behavior across chronic conditions (Perez-Jover et al). Roughly two-thirds of U.S. consumers have used a health app in the past year, which gives the pharmacy team a credible delivery channel for patients who already manage other health information on their phones.

The investment trade-off for health systems is the cost of app onboarding and ongoing engagement versus the cost of avoidable readmissions and lost therapy persistence. For specialty pharmacies in particular, app-based adherence support pairs well with the smart-bottle and predictive-model layers already in place.

 

  1. AI chatbots for patient support

Conversational AI in pharmacy contact centers and specialty enrollment teams handles routine questions, surfaces patterns across calls, and frees the pharmacy team to focus on the harder conversations that need human judgment. The chatbots collect data on medication-taking habits, flag potential side effects or barriers to adherence, and route higher-risk conversations to a pharmacist or member advocate.

A systematic review of AI-based chatbots for promoting health behavior changes found consistent evidence that conversational AI can support adherence behaviors when paired with clinician follow-up (Aggarwal et al). The principle is the same in pharmacy: the chatbot scales the first layer of contact, but the pharmacist still owns the clinical decision and the relationship.

VytlOne’s own contact center is a working example of this approach. AI transcribes and analyzes member calls to surface adherence themes, deliver real-time coaching to member advocates, and prepare for AI-powered call summarization that reduces administrative load without reducing the human contact members value (see “Embracing AI Without Losing the Human Touch”).

 

  1. FDA-approved smart drug-device combinations

Some adherence tools are built into the medication itself. The FDA approved its first digital drug-device combination nearly a decade ago: a tablet embedded with an ingestible sensor that confirmed each dose and transmitted the data to the provider. Smart insulin pens and connected inhalers followed, all designed to give clinicians real-time visibility into whether the patient is actually taking the drug as prescribed.

Health systems and specialty pharmacies managing chronic-disease programs use these combinations inside high-acuity workflows where the cost of non-adherence is measurable in hospital admissions and disease progression (Vallejos and Wu). For complex regimens with narrow therapeutic windows, the device data tells the pharmacist whether the next step is patient education, dose adjustment, or a different therapy entirely.

Smart drug-device combinations are not a fit for every patient or every medication. The selection criteria are clinical: the drug has to be costly enough or risky enough that real-time confirmation matters, and the patient has to consent to the data sharing. When those conditions hold, the device shortens the loop between dose and decision (Zijp et al).

 

How VytlAIQ supports medication adherence

VytlAIQ brings the mechanisms covered above into one operating layer for the pharmacy team. The platform’s predictive intelligence scores adherence risk using the same kinds of inputs (pharmacy claims, EHR data, connected-device signals, and social determinants) and surfaces the patients most likely to drop off therapy in the next 7 to 30 days. Pharmacists see the risk scores and the contributing factors inside their existing workflow, not buried in a separate dashboard. 

The Liaison Intelligence module turns those risk scores into next-best-action recommendations for the pharmacy liaison or technician making the outreach call. Workflow automation handles documentation and routing, which frees the pharmacist to focus on the conversation that actually moves the patient. For health systems running AI specialty pharmacy or AI 340B optimization programs alongside adherence work, VytlAIQ keeps all three on the same data layer, so a flagged adherence risk on a high-cost specialty patient triggers the right escalation without anyone retyping data into a second system.

VytlAIQ is designed to amplify the pharmacist’s judgment, not replace it. The platform handles the data work. The pharmacist handles the decision.

Risks and limits of AI in medication adherence

AI in medication adherence is not a finished technology, and treating it like one creates real risk. Three areas deserve specific attention from health-system buyers.

Model bias. Predictive adherence models underperform in patient populations they were not adequately trained on, including older adults with cognitive impairment, patients with limited digital literacy, and patients facing language or affordability barriers. Subgroup validation, fairness testing, and drift monitoring are baseline requirements, not optional features (Solomon).

Data privacy. AI tools handle protected health information at scale. HIPAA compliance is necessary but not sufficient. Health systems should also evaluate the data-sharing posture of the vendor, the audit logging available to the buyer, and the governance over which decisions the AI supports versus which decisions stay with the pharmacist.

Replacement risk. AI does not replace the pharmacist conversation. Risk scores are decision support. The pharmacist owns the clinical decision, the patient relationship, and the judgment calls AI cannot make, especially in the patient populations where the models are least reliable.

Final thoughts

Improving medication adherence benefits everyone. It leads to better patient outcomes, fewer hospitalizations, and significant cost savings. With AI, we have new tools to identify, support, and engage patients in ways that make a real impact.

Further reading

 

How does AI improve medication adherence?

AI improves medication adherence by predicting which patients are most likely to miss doses, surfacing those patterns to the pharmacy team in real time, and routing the right intervention to the right patient at the right moment. Machine-learning models combine pharmacy claims, EHR data, connected-device signals, and social determinants to flag 7- to 30-day non-adherence risk with AUC values of 0.75 to 0.85. Pharmacists then prioritize outreach to the highest-risk patients before a missed refill would have caught the problem. The result is earlier intervention, better therapy persistence, and fewer avoidable hospitalizations.

What is AI-powered medication adherence?

AI-powered medication adherence is the use of predictive models, smart devices, conversational AI, and drug-device combinations to help patients take their medications as prescribed. The technology layer collects dosing events, behavioral signals, and physiologic data, then surfaces patterns that the pharmacy team can act on. Smart pill bottles record when each dose is taken. Wearables capture sleep, mobility, and other context. Machine-learning models combine those inputs with EHR and claims data to predict short-term non-adherence risk. The pharmacist interprets the signal and decides on the intervention. The technology scales the data work. The pharmacist owns the clinical judgment.

Is AI-powered medication adherence HIPAA-compliant?

AI-powered medication adherence tools handle protected health information, so HIPAA compliance is a baseline requirement for any platform a health system or specialty pharmacy deploys. Compliant tools encrypt data at rest and in transit, restrict access through role-based controls, log every data access for audit, and route patient information only through Business Associate Agreement-covered systems. The selection criteria for buyers should also include subgroup performance testing for bias, transparency about model inputs, and clear governance over which decisions the AI supports versus which decisions stay with the pharmacist. Compliance is necessary but not sufficient.

How should a health system get started with AI for medication adherence?

The most validated and operationally scalable entry point for pharmacy AI is medication adherence. A practical sequence starts with stabilizing the medication regimen for the highest-risk patient population, then layering in a smart pill bottle or predictive model where the cost of non-adherence is highest, usually in specialty pharmacy or chronic-disease programs. Track outcomes such as therapy persistence, hospitalization rate, and pharmacist intervention volume. Once those wins are documented, scale to additional patient populations and additional adherence layers. Governance, workflow integration, and pharmacist training matter at every step.

Where does the pharmacist fit when AI handles adherence monitoring?

The pharmacist owns the clinical decision and the patient relationship. AI handles the data work that pharmacists do not have the time to do at scale: scoring risk across thousands of patients, surfacing patterns across calls and devices, automating documentation and routing. The pharmacist interprets the signal in context, makes the call on the intervention, and follows up with the patient. Risk scores are decision support, not decision replacement. Predictive models underperform in some patient populations, including those with cognitive impairment or limited digital literacy, so the pharmacist’s judgment matters most in exactly the cases where AI is least reliable.

References

Learn more

Curious how Vytlone can help you improve the value of your pharmacy? Contact us here.

 

Scroll to Top

Contact Member Services


Caller Name:
Callback #:




Contact the Pharmacy

Contact our pharmacy support staff by entering your information below or by calling us at 1 (800) 658-6046.

This field is for validation purposes and should be left unchanged.

vytl logo
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.